Ketamine only
Phase 1Small molecule
Ketamine only is one of 7 small molecule programs targeting Major Depressive Disorder (MDD). It is currently in Phase 1.
1
Indications
5
Total Trials
2
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Major Depressive Disorder (MDD)
#DrugCompanyPhaseTrials
1Ketalar
Boehringer IngelheimApproved
Thiamine
UUniversiti Kebangsaan Malaysia Medical Centre
Phase 2
CYB003
CCybin IRL Limited
Phase 3
PET Scan With VAT
SStony Brook University
Phase 3
Celebrex
PPhiladelphia Eye Associates
Preclinical
SPT-300
SSeaport Therapeutics
Phase 2
Ketamine only
UUniversity of Pennsylvania
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Post Spinal Anesthesia Shivering1 trial
Pediatric1 trial
Ketamine/Propofol vs Ketamine Alone for Pediatric Fracture Reduction
Completed·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 4·NCT00490997·140 enrolled
Post Operative Pain1 trial
Low-Dose Ketamine Infusion for Post-Operative Pain in Patients Undergoing Laparoscopic Cholecyctectomy
Completed·—·Phase 1·NCT06966596·116 enrolled
Major Depressive Disorder (MDD)1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ketamine only. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- UUniversity of Pennsylvania